Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Rang in aandelen #16450
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Aandeelprijs
$4.64
Laatst gesynchroniseerd: 2022-09-12
Marktkapitalisatie
$293.43M
Verandering (1 dag)
0.87%
Verandering (1 jaar)
0.00%
Land
US
Handel Adagio Therapeutics, Inc. (ADGI)

Categorie

P/S-ratio voor Adagio Therapeutics, Inc. (ADGI)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Adagio Therapeutics, Inc. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Adagio Therapeutics, Inc. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH